{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T21:23:46Z","timestamp":1783113826453,"version":"3.54.6"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Mol Allergy"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Dipeptidyl peptidase-IV (DPP-IV) inhibitors, also known as gliptins, are a class of oral antidiabetic agents. Postmarketing reports have documented the occurrence of angioedema in patients treated with gliptins and it was found that these drugs increased the risk of angioedema in patients concurrently treated with angiotensin-converting enzyme inhibitors (ACEIs). The aim of this manuscript is to provide an overview of the risk of angioedema associated with gliptins.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The keywords used for the literature search in the PubMed database included \u201cangioedema\u201d and \u201cdipeptidyl peptidase\u201d, \u201cgliptins\u201d, or the name of each DPP-IV inhibitor. Articles in English published up to December 2020 were taken into consideration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The available data appear to rule out a higher risk of angioedema associated with gliptin monotherapy and have revealed an increased susceptibility in patients simultaneously treated with gliptins and ACEIs. However, one single multicenter phase IV trial and case reports, even if very limited in number, have shown that angioedema can also occur during treatment with DPP-IV inhibitors without the concomitant use of ACEIs. The involvement of other drugs and drug interactions has occasionally been suggested. In a few patients, deficiency of enzymes involved in bradykinin catabolism was detected and this finding can constitute a risk factor for angioedema exacerbated by treatment with DPP-IV inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This risk of angioedema associated with the use of gliptins has mostly been related to the concurrent administration of ACEIs, and has been considered rare, but it might be underestimated and underreported. The role of additional risk factors or drug interactions deserves further investigations. Caution should be taken when considering the use of DPP-IV inhibitors in patients treated with ACEIs or presenting with other known risk factors for angioedema.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12948-021-00164-7","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T07:02:28Z","timestamp":1638774148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Angioedema associated with dipeptidyl peptidase-IV inhibitors"],"prefix":"10.1186","volume":"19","author":[{"given":"Nicoletta","family":"Cassano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9916-8211","authenticated-orcid":false,"given":"Elisabetta","family":"Di Leo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Ambrogio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gino A.","family":"Vena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Foti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"issue":"4","key":"164_CR1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.beem.2009.03.004","volume":"23","author":"NA Thornberry","year":"2009","unstructured":"Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479\u201386.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"164_CR2","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"7","key":"164_CR3","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1016\/j.jaip.2020.03.015","volume":"8","author":"M Lepelley","year":"2020","unstructured":"Lepelley M, Khouri C, Lacroix C, Bouillet L. Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor-induced angioedema: a disproportionality analysis of the WHO pharmacovigilance database. J Allergy Clin Immunol Pract. 2020;8(7):2406-8.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"164_CR4","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0196-9781(96)00201-X","volume":"17","author":"JS Russell","year":"1996","unstructured":"Russell JS, Chi H, Lantry LE, Stephens RE, Ward PE. Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides. 1996;17(8):1397\u2013403.","journal-title":"Peptides"},{"issue":"3","key":"164_CR5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/HYPERTENSIONAHA.109.134197","volume":"54","author":"NJ Brown","year":"2009","unstructured":"Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009;54(3):516\u201323.","journal-title":"Hypertension"},{"issue":"3","key":"164_CR6","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2017.04.006","volume":"37","author":"C Stone Jr","year":"2017","unstructured":"Stone C Jr, Brown NJ. Angiotensin-converting enzyme inhibitor and other drug-associated angioedema. Immunol Allergy Clin N Am. 2017;37(3):483\u201395.","journal-title":"Immunol Allergy Clin N Am"},{"issue":"Suppl 2","key":"164_CR7","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.2337\/dc11-s229","volume":"34","author":"D Dicker","year":"2011","unstructured":"Dicker D. DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors. Diabetes Care. 2011;34(Suppl 2):S276\u20138.","journal-title":"Diabetes Care"},{"issue":"3","key":"164_CR8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.amjcard.2012.03.034","volume":"110","author":"H Makani","year":"2012","unstructured":"Makani H, Messerli FH, Romero J, Wever-Pinzon O, Korniyenko A, Berrios RS, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol. 2012;110(3):383\u201391.","journal-title":"Am J Cardiol"},{"issue":"1","key":"164_CR9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13023-018-0815-5","volume":"13","author":"E Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2018","unstructured":"Ayg\u00f6ren-P\u00fcrs\u00fcn E, Magerl M, Maetzel A, Maurer M. Epidemiology of Bradykinin-mediated angioedema: a systematic investigation of epidemiological studies. Orphanet J Rare Dis. 2018;13(1):73.","journal-title":"Orphanet J Rare Dis"},{"key":"164_CR10","doi-asserted-by":"crossref","first-page":"106081","DOI":"10.1016\/j.intimp.2019.106081","volume":"78","author":"V Montinaro","year":"2020","unstructured":"Montinaro V, Cicardi M. ACE inhibitor-mediated angioedema. Int Immunopharmacol. 2020;78:106081.","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"164_CR11","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S1081-1206(10)60594-7","volume":"100","author":"A Banerji","year":"2008","unstructured":"Banerji A, Clark S, Blanda M, LoVecchio F, Snyder B, Camargo CA Jr. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol. 2008;100(4):327\u201332.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"164_CR12","doi-asserted-by":"crossref","first-page":"272","DOI":"10.18176\/jiaci.0458","volume":"30","author":"L Carucci","year":"2020","unstructured":"Carucci L, Bova M, Petraroli A, Ferrara AL, Sutic A, de Crescenzo G, et al. Angiotensin-converting enzyme inhibitor-associated angioedema: from bed to bench. J Investig Allergol Clin Immunol. 2020;30(4):272\u201380.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"164_CR13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0009-9236(96)90161-7","volume":"60","author":"NJ Brown","year":"1996","unstructured":"Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996;60(1):8\u201313.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"164_CR14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2753.2003.00484.x","volume":"10","author":"T Morimoto","year":"2004","unstructured":"Morimoto T, Gandhi TK, Fiskio JM, Seger AC, So JW, Cook EF, et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract. 2004;10(4):499\u2013509.","journal-title":"J Eval Clin Pract"},{"issue":"7551","key":"164_CR15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","volume":"332","author":"SE McDowell","year":"2006","unstructured":"McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ. 2006;332(7551):1177\u201381.","journal-title":"BMJ"},{"issue":"3","key":"164_CR16","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jaip.2017.02.018","volume":"5","author":"A Banerji","year":"2017","unstructured":"Banerji A, Blumenthal KG, Lai KH, Zhou L. Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract. 2017;5(3):744\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"14","key":"164_CR17","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/archinte.165.14.1637","volume":"165","author":"JB Kostis","year":"2005","unstructured":"Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J, et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med. 2005;165(14):1637\u201342.","journal-title":"Arch Intern Med"},{"issue":"6","key":"164_CR18","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/bcp.13090","volume":"82","author":"SH Mahmoudpour","year":"2016","unstructured":"Mahmoudpour SH, Baranova EV, Souverein PC, Asselbergs FW, de Boer A, Maitland-van der Zee AH, PREDICTION-ADR consortium. Determinants of angiotensin-converting enzyme inhibitor (ACEI) intolerance and angioedema in the UK Clinical Practice Research Datalink. Br J Clin Pharmacol. 2016;82(6):1647\u201359.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"164_CR19","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1398-9995.2010.02398.x","volume":"65","author":"JB Byrd","year":"2010","unstructured":"Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, et al. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy. 2010;65(11):1381\u20137.","journal-title":"Allergy"},{"issue":"6","key":"164_CR20","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1161\/HYPERTENSIONAHA.108.110270","volume":"51","author":"DR Miller","year":"2008","unstructured":"Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624\u201330.","journal-title":"Hypertension"},{"issue":"7","key":"164_CR21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11906-018-0859-x","volume":"20","author":"WJ Kostis","year":"2018","unstructured":"Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE inhibitor-induced angioedema: a review. Curr Hypertens Rep. 2018;20(7):55.","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"164_CR22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3109\/07853890.2014.949300","volume":"46","author":"M Pedrosa","year":"2014","unstructured":"Pedrosa M, Prieto-Garc\u00eda A, Sala-Cunill A, Spanish Group for the Study of Bradykinin-Mediated Angioedema (SGBA) and the Spanish Committee of Cutaneous Allergy (CCA). Management of angioedema without urticaria in the emergency department. Ann Med. 2014;46(8):607\u201318.","journal-title":"Ann Med"},{"issue":"3","key":"164_CR23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jaip.2017.03.017","volume":"5","author":"SN Hudey","year":"2017","unstructured":"Hudey SN, Westermann-Clark E, Lockey RF. Cardiovascular and diabetic medications that cause bradykinin-mediated angioedema. J Allergy Clin Immunol Pract. 2017;5(3):610\u20135.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"164_CR24","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaci.2007.04.012","volume":"120","author":"JB Byrd","year":"2007","unstructured":"Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, et al. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007;120(2):403\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"164_CR25","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/HYPERTENSIONAHA.107.096552","volume":"51","author":"JB Byrd","year":"2008","unstructured":"Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008;51(1):141\u20137.","journal-title":"Hypertension"},{"issue":"2 Pt 2","key":"164_CR26","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/hy0202.103054","volume":"39","author":"J Lefebvre","year":"2002","unstructured":"Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002;39(2 Pt 2):460\u20134.","journal-title":"Hypertension"},{"issue":"4","key":"164_CR27","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/00015385.2018.1507477","volume":"74","author":"L Davin","year":"2019","unstructured":"Davin L, Marechal P, Lancellotti P, Martinez C, Pierard L, Radermecker R. Angioedema: a rare and sometimes delayed side effect of angiotensin-converting enzyme inhibitors. Acta Cardiol. 2019;74(4):277\u201381.","journal-title":"Acta Cardiol"},{"issue":"3","key":"164_CR28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/HYPERTENSIONAHA.109.135244","volume":"54","author":"E Grouzmann","year":"2009","unstructured":"Grouzmann E, Livio F, Buclin T. Angiotensin-converting enzyme and dipeptidyl peptidase IV inhibitors: an increased risk of angioedema. Hypertension. 2009;54(3):468\u201370.","journal-title":"Hypertension"},{"issue":"4","key":"164_CR29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/1573399813666170214113856","volume":"14","author":"SI Scott","year":"2018","unstructured":"Scott SI, Andersen MF, Aagaard L, Buchwald CV, Rasmussen ER. Dipeptidyl peptidase-4 inhibitor induced angioedema\u2014an overlooked adverse drug reaction? Curr Diabetes Rev. 2018;14(4):327\u201333.","journal-title":"Curr Diabetes Rev"},{"issue":"3","key":"164_CR30","doi-asserted-by":"crossref","first-page":"e00084","DOI":"10.1002\/edm2.84","volume":"2","author":"R Williams","year":"2019","unstructured":"Williams R, Kothny W, Serban C, Lopez-Leon S, de Vries F, Schlienger R. Association between vildagliptin and risk of angioedema, foot ulcers, skin lesions, hepatic toxicity, and serious infections in patients with type 2 diabetes mellitus: A European multidatabase, noninterventional, postauthorization safety study. Endocrinol Diabetes Metab. 2019;2(3):e00084.","journal-title":"Endocrinol Diabetes Metab"},{"key":"164_CR31","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1472-6823-8-14","volume":"8","author":"D Williams-Herman","year":"2008","unstructured":"Williams-Herman D, Round E, Swern AS, Musser B, Davies MJ, Stein PP, et al. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocr Disord. 2008;8:14.","journal-title":"BMC Endocr Disord"},{"key":"164_CR32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1472-6823-10-7","volume":"10","author":"D Williams-Herman","year":"2010","unstructured":"Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.","journal-title":"BMC Endocr Disord"},{"issue":"7","key":"164_CR33","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/dmrr.2502","volume":"30","author":"B Hirshberg","year":"2014","unstructured":"Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30(7):556\u201369.","journal-title":"Diabetes Metab Res Rev"},{"issue":"14","key":"164_CR34","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, SAVOR-TIMI 53 Steering Committee and Investigators, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"key":"164_CR35","unstructured":"Cardiovascular outcomes study of alogliptin in patients with type 2 diabetes and acute coronary syndrome (EXAMINE). Study results. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT00968708."},{"issue":"6","key":"164_CR36","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/20009666.2019.1698259","volume":"9","author":"A Pfaue","year":"2019","unstructured":"Pfaue A, Schuler PJ, Mayer B, Hoffmann TK, Greve J, Hahn J. Clinical features of angioedema induced by renin-angiotensin-aldosterone system inhibition: a retrospective analysis of 84 patients. J Community Hosp Intern Med Perspect. 2019;9(6):453\u20139.","journal-title":"J Community Hosp Intern Med Perspect"},{"issue":"3","key":"164_CR37","first-page":"119","volume":"46","author":"E Beaudouin","year":"2014","unstructured":"Beaudouin E, Defendi F, Picaud J, Drouet C, Ponard D, Moneret-Vautrin DA. Iatrogenic angioedema associated with ACEi, sitagliptin, and deficiency of 3 enzymes catabolizing bradykinin. Eur Ann Allergy Clin Immunol. 2014;46(3):119\u201322.","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"12","key":"164_CR38","first-page":"863","volume":"42","author":"G Gabb","year":"2013","unstructured":"Gabb G, Andrew N. Lump in the throat\u2014a case study. Aust Fam Physician. 2013;42(12):863\u20136.","journal-title":"Aust Fam Physician"},{"issue":"8","key":"164_CR39","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.2337\/dc12-0574","volume":"35","author":"AR Gosmanov","year":"2012","unstructured":"Gosmanov AR, Fontenot EC. Sitagliptin-associated angioedema. Diabetes Care. 2012;35(8):e60.","journal-title":"Diabetes Care"},{"key":"164_CR40","doi-asserted-by":"crossref","first-page":"576","DOI":"10.12659\/AJCR.901960","volume":"18","author":"J Hahn","year":"2017","unstructured":"Hahn J, Trainotti S, Hoffmann TK, Greve J. Drug-induced inhibition of angiotensin converting enzyme and dipeptidyl peptidase 4 results in nearly therapy resistant bradykinin induced angioedema: a case report. Am J Case Rep. 2017;18:576\u20139.","journal-title":"Am J Case Rep"},{"key":"164_CR41","doi-asserted-by":"crossref","first-page":"bcr2016217802","DOI":"10.1136\/bcr-2016-217802","volume":"2017","author":"T Hermanrud","year":"2017","unstructured":"Hermanrud T, Bygum A, Rasmussen ER. Recurrent angioedema associated with pharmacological inhibition of dipeptidyl peptidase IV. BMJ Case Rep. 2017;2017:bcr2016217802.","journal-title":"BMJ Case Rep"},{"issue":"5","key":"164_CR42","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1093\/bja\/aes371","volume":"109","author":"I Millot","year":"2012","unstructured":"Millot I, Plancade D, Hosotte M, Landy C, Nadaud J, Ragot C, et al. Treatment of a life-threatening laryngeal bradykinin angio-oedema precipitated by dipeptidylpeptidase-4 inhibitor and angiotensin-I converting enzyme inhibitor with prothrombin complex concentrates. Br J Anaesth. 2012;109(5):827\u20139.","journal-title":"Br J Anaesth"},{"issue":"4","key":"164_CR43","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1111\/dme.12134","volume":"30","author":"Y Saisho","year":"2013","unstructured":"Saisho Y, Itoh H. Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect? Diabet Med. 2013;30(4):e149\u201350.","journal-title":"Diabet Med"},{"issue":"4","key":"164_CR44","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1464-5491.2010.02973.x","volume":"27","author":"S Skalli","year":"2010","unstructured":"Skalli S, Wion-Barbot N, Baudrant M, Lablanche S, Benhamou PY, Halimi S. Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report. Diabet Med. 2010;27(4):486\u20137.","journal-title":"Diabet Med"},{"issue":"3","key":"164_CR45","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/j.ijcard.2013.07.257","volume":"168","author":"H Hamasaki","year":"2013","unstructured":"Hamasaki H, Yanai H. The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin. Int J Cardiol. 2013;168(3):e106.","journal-title":"Int J Cardiol"},{"issue":"2","key":"164_CR46","doi-asserted-by":"crossref","first-page":"142","DOI":"10.7326\/L16-0649","volume":"167","author":"R Arcani","year":"2017","unstructured":"Arcani R, Martinez S, Gayet S. Sitagliptin and angioedema. Ann Intern Med. 2017;167(2):142\u20133.","journal-title":"Ann Intern Med"},{"issue":"6","key":"164_CR47","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/j.jaip.2019.02.008","volume":"7","author":"A Schneider","year":"2019","unstructured":"Schneider A, Ramesh M. Angioedema following initiation of glecaprevir\/pibrentasvir while on sitagliptin. J Allergy Clin Immunol Pract. 2019;7(6):2068\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"164_CR48","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001214","author":"A Yeddi","year":"2020","unstructured":"Yeddi A, Abdelhai M, Mohamed AB, Yeddi O, Salih L, Ali M, et al. Alogliptin-associated angioedema: case report and review of the literature. Am J Ther. 2020. https:\/\/doi.org\/10.1097\/MJT.0000000000001214.","journal-title":"Am J Ther"},{"issue":"4","key":"164_CR49","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/ACI.0b013e328362b835","volume":"13","author":"P Campo","year":"2013","unstructured":"Campo P, Fernandez TD, Canto G, Mayorga C. Angioedema induced by angiotensin converting enzyme inhibitors. Curr Opin Allergy Clin Immunol. 2013;13(4):337\u201344.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"164_CR50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14740338.2018.1444027","volume":"17","author":"AJ Scheen","year":"2018","unstructured":"Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387\u2013405.","journal-title":"Expert Opin Drug Saf"}],"container-title":["Clinical and Molecular Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12948-021-00164-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12948-021-00164-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T07:04:21Z","timestamp":1638774261000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalmolecularallergy.biomedcentral.com\/articles\/10.1186\/s12948-021-00164-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["164"],"URL":"https:\/\/doi.org\/10.1186\/s12948-021-00164-7","relation":{},"ISSN":["1476-7961"],"issn-type":[{"value":"1476-7961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"25 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}